 |
|
|
|
 |
|
|
| Article 1 to 10 out of 18 concerning PhotoCure ASA
|
-
Photocure granted patent in Europe and Russia for Visonac in the treatment of acne
(01 Dec 2009)
Both the European Patent Office and the Patent Office in Russia have issued decisions to grant a patent on Photocure's patent application "PDT Acne". The granted patents will provide protection for the use of the 5-ALA-ester methyl aminolevulinate ...
-
Photocure divests Metvix to Galderma for EUR 51 million
(02 Oct 2009)
Photocure ASA has entered into agreements with Galderma S.A., under which Galderma has purchased global rights, assets, and liabilities related to Metvix and Metvixia, as well as the exclusive right to develop new dermatology products based on ...
-
Photocure wins patent case in USA
(07 Apr 2009)
In September 2004, Photocure submitted to the United States Patent Office (USPTO) an application for patent term extension of its US patent covering its FDA-approved drug product Metvixia(TM). US law permits patent term extension due to the lengthy ...
-
Photocure receives a grant of NOK 4.3 mill from the Norwegian Research Counsel
(17 Feb 2009)
Photocure was rewarded NOK 4.3 mill (~€ 0.5 mill) over 3 years from the BIA program of the Norwegian Research Counsel (NFR). The BIA program supports highly innovative projects that create value to both the company and society. Photocure has ...
-
Photocure’s Cevira shows positive interim results for treatment of precancerous lesions of the cervix
(18 Nov 2008)
Six-month interim data presented at international conference addressing prevention of cervical cancer
Photocure presented positive interim data at the six-month follow up stage of its phase I/II clinical feasibility study with Cevira™ at the EUROGIN 2008 international conference. Cevira™ is Photocure’s photodynamic therapy (PDT) in development as a ...
-
Phase III study results demonstrate that Hexvix cystoscopy for bladder cancer leads to significantly improved patient outcome
(16 Sep 2008)
PhotoCure announced results from a phase III clinical study showing that fluorescence cystoscopy of the bladder using Hexvix (hexaminolevulinate) significantly improves the detection of non-invasive papillary bladder cancer. As a result of this ...
-
Metvixia and Aktilite CL128 approved by FDA
(30 Jun 2008)
Photocure ASA announces that Metvixia(TM) in combination with Aktilite® CL128, the LED based narrow band (630 nm) red light technology device has been approved by US Food and Drug Administration (FDA) for the treatment of actinic keratosis (AK), a ...
-
Photocure receives grant of MNOK 9.1 from the Research Council of Norway
(07 Apr 2008)
Photocure has been awarded NOK 9.1 million for the next three years from The Research Council of Norway (RCN) high-profile programme "User-driven Research-based Innovation" (BIA). Photocure received the grant for the project "Early detection of ...
-
PCI Biotech strengthens the management team
(06 Feb 2008)
PCI Biotech, Photocure's cancer-focused drug delivery subsidiary, strenghtens the management team and hires Per Walday as CEO.Mr Per Walday has been appointed as new CEO of PCI Biotech starting in the second quarter of 2008. Mr Anders Høgset, ...
-
Photocure announces plans to de-merge PCI Biotech
(19 Nov 2007)
Photocure ASA announced that its Board of Directors has decided to a plan to de-merge PCI Biotech, its cancer-focused drug delivery subsidiary. Following the completion of the de-merger process, PCI Biotech intends to seek a public listing on the ...
Additional information
PhotoCure ASA
Oslo, Norway
Company
|
|
|
|
|
|
Top
